Pharm5

Pharm5

By Elizabeth B. Hearn, PharmD, BCACPMedicineHealth & Fitness
Download on the App Store

Pharm5 episodes

  • April 1, 2022

    This week on Pharm5:

    • New COVID booster recommendations
    • Transdermal dextroamphetamine for ADHD
    • No ivermectin for COVID-19
    • North Carolina’s workplace condition complaint form
    • ASHP Phase II rank list due Wednesday, April 6th


      • Connect with us!

      • Listen to our podcast: Pharm5
      • Watch us on TikTok: @LizHearnPharmD
      • Follow us on Twitter: @LizHearnPharmD


        • References:

        1. CDC recommends additional boosters for certain individuals. Centers for Disease Control and Prevention. https://www.cdc.gov/media/releases/2022/s0328-covid-19-boosters.html.  Published March 29, 2022. Accessed March 31, 2022.
        2. Pfizer and BioNTech submit for U.S. emergency use authorization of an additional booster dose of their COVID-19 vaccine for older adults. Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-us-emergency-use-authorization. Published March 15, 2022. Accessed March 16, 2022.
        3. FDA Approves Xelstrym. https://www.drugs.com/newdrugs/fda-approves-xelstrym-dextroamphetamine-transdermal-attention-deficit-hyperactivity-disorder-adhd-5805.html.   Published March 23, 2022. Accessed March 23, 2022.
        4. Reis G, Silva EASM, Silva DCM, et al. Effect of early treatment with ivermectin among patients with covid-19. New England Journal of Medicine. 2022. doi:10.1056/nejmoa2115869
        5. Working Conditions Complaint Form. http://www.ncbop.org/NewsItems/WorkingConditionsComplaintForm.html. Accessed March 31, 2022.
        6. Schedule of dates. ASHP Match | Schedule. https://natmatch.com/ashprmp/schedule.html. Published January 6, 2022. Accessed March 16, 2022.
          7. 4 min
        7. March 25, 2022

          This week on Pharm5:

          • Ztalmy (ganaxolone) for CDKL5-CDD seizure disorder
          • Opdualag (nivolumab/relatlimab-rmbw) for metastatic melanoma
          • Missouri HB1677 for PBM transparency
          • COVID-19 linked with increased risk and burden of T2DM
          • APhA elections open until April 18th


            • Connect with us!

            • Listen to our podcast: Pharm5
            • Watch us on TikTok: @LizHearnPharmD
            • Follow us on Twitter: @LizHearnPharmD


              • References:

              1. Ztalmy. Package insert. Marinus Pharmaceuticals, Inc; 2022.
              2. Opdualag. Package insert. Bristol-Myers Squibb Company; 2022.
              3. Erickson K. Missouri lawmakers seek lower drug prices with plan to regulate pharmacy benefit managers. STLtoday.com. https://www.stltoday.com/news/local/govt-and-politics/missouri-lawmakers-seek-lower-drug-prices-with-plan-to-regulate-pharmacy-benefit-managers/article_c0447e7b-af83-5c53-8dac-bf3eecca0cee.html. Published March 23, 2022. Accessed March 23, 2022.
              4. Becker C. State policy options and Pharmacy Benefit Managers (pbms). https://www.ncsl.org/research/health/state-policy-options-and-pharmacy-benefit-managers.aspx#/. Accessed March 23, 2022.
              5. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long covid: A cohort study. The Lancet Diabetes & Endocrinology. March 2022:1-11. doi:10.1016/s2213-8587(22)00044-4. 
              6. Election Information. American Pharmacists Association. https://www.pharmacist.com/apha-elections. Accessed March 24, 2022.
                7. 4 min
              7. March 18, 2022

                This week on Pharm5:

                • ASHP Match Results
                • Generic Symbicort Approved
                • Lynparza reduces death 32% in HER2-neg, gBRCAm breast cancer
                • Congress passes 340B protection
                • 4th Pfizer COVID vaccine


                  • Connect with us!

                  • Listen to our podcast: Pharm5
                  • Watch us on TikTok: @LizHearnPharmD
                  • Follow us on Twitter: @LizHearnPharmD


                    • References:

                    1. Schedule of dates. ASHP Match | Schedule. https://natmatch.com/ashprmp/schedule.html. Published January 6, 2022. Accessed March 16, 2022.
                    2. Commissioner of the FDA approves first generic of Symbicort to treat asthma and COPD. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-symbicort-treat-asthma-and-copd?utm_campaign=%2BFDA%2BApproves%2BFirst%2BGeneric%2Bof%2BSymbicort%2Bto%2BTreat%2BAsthma%2Band%2BCOP&utm_medium=email&utm_source=govdelivery. Accessed March 17, 2022.
                    3. Lynparza® (OLAPARIB) reduced risk of death by 32% in patients with germline BRCA-mutated, HER2-negative high-risk early breast cancer in phase 3 olympia trial. Merck.com. https://www.merck.com/news/lynparza-olaparib-reduced-risk-of-death-by-32-in-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer-in-phase-3-olympia-trial/. Published March 17, 2022. Accessed March 17, 2022.
                    4. Congress passes omnibus spending bill with 340B DSH protection, telehealth provisions. ASHP. https://www.ashp.org/news/2022/03/11/congress-passes-omnibus-spending-bill-340b-dsh-eligibility?loginreturnUrl=SSOCheckOnly. Published March 11, 2022. Accessed March 16, 2022.
                    5. Pfizer and BioNTech submit for U.S. emergency use authorization of an additional booster dose of their COVID-19 vaccine for older adults. Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-us-emergency-use-authorization. Published March 15, 2022. Accessed March 16, 2022.
                      6. 5 min
                    6. March 11, 2022

                      This week on Pharm5:

                      • AMA against pharmacy-based test-to-treat
                      • Expanding pharmacist roles
                      • Kaleo’s naloxone auto-injector
                      • E-cigarettes increase odds of pre-diabetes
                      • 2 years later, COVID-19 deaths hit 6 million


                        • Connect with us!

                        • Listen to our podcast: Pharm5
                        • Watch us on TikTok: @LizHearnPharmD
                        • Follow us on Twitter: @LizHearnPharmD


                          • References:

                          1. AMA statement on Administration's test-to-treat COVID-19 plan. American Medical Association. https://www.ama-assn.org/press-center/press-releases/ama-statement-administration-s-test-treat-covid-19-plan. Published March 4, 2022. Accessed March 10, 2022.
                          2. March 9, 2022 president Joseph R. Biden the White House. https://www.ashp.org/-/media/assets/advocacy-issues/docs/GRD-Joint-Pharm-Org-Letter-To-WH-on-Test-to-Treat-2022. Accessed March 10, 2022.
                          3. Sartain M. CDC makes the case for pharmacists’ reimbursement given expanding roles. American Pharmacists Association. https://www.pharmacist.com/Pharmacy-News/cdc-makes-the-case-for-pharmacists-reimbursement-given-expanding-roles. Published March 7, 2022. Accessed March 10, 2022.
                          4. Ashley Gallagher AE. FDA approves 10-mg naloxone injection to treat exposure to ultra-potent weaponized opioids. Pharmacy Times. https://www.pharmacytimes.com/view/fda-approves-10-mg-naloxone-injection-to-treat-exposure-to-ultra-potent-weaponized-opioids. Published March 4, 2022. Accessed March 10, 2022.
                          5. BioSpace. FDA approves Kaléo's 10 mg naloxone auto-injector for the treatment of known or potential exposure to ultra-potent weaponized opioids. BioSpace. https://www.biospace.com/article/releases/fda-approves-kaleo-s-10-mg-naloxone-auto-injector-for-the-treatment-of-known-or-potential-exposure-to-ultra-potent-weaponized-opioids/. Published March 2, 2022. Accessed March 10, 2022.
                          6. The surprising truth about prediabetes. Centers for Disease Control and Prevention. https://www.cdc.gov/diabetes/library/features/truth-about-prediabetes.html. Published December 21, 2021. Accessed March 10, 2022.
                          7. Rizzo S, Nirappil F. Global covid-19 death toll tops 6 million, another grim milestone in the pandemic. The Washington Post. https://www.washingtonpost.com/health/2022/03/07/6-million-covid-deaths/.  Published March 7, 2022. Accessed March 10, 2022.
                          8. CDC Museum Covid-19 Timeline. Centers for Disease Control and Prevention. https://www.cdc.gov/museum/timeline/covid19.html. Published January 5, 2022. Accessed March 10, 2022.
                          9. Holder J. Tracking coronavirus vaccinations around the world. The New York Times. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html.  Published January 29, 2021. Accessed March 10, 2022.
                            10. 4 min
                          10. March 4, 2022

                            This week on Pharm5:

                            • Jardiance indicated for heart failure
                            • Drug prices in the SOTU address
                            • Vonjo approved for cytopenic myelofibrosis
                            • One Male Condom marketed for anal intercourse
                            • ASHP Phase I rank list due 11:59 PM


                              • Connect with us!

                              • Listen to our podcast: Pharm5
                              • Watch us on TikTok: @LizHearnPharmD
                              • Follow us on Twitter: @LizHearnPharmD


                                • Thank you to Abigail Hulsizer, PharmD, BCPS and student pharmacist Kristopher S. Ingram for your contributions to this episode! 


                                References:

                                1. FDA Approves Treatment for Wider Range of Patients with Heart Failure https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-wider-range-patients-heart-failure. Published February 24, 2022. Accessed February 24, 2022.
                                2. Jardiance.com. https://www.jardiance.com/heart-failure/. Accessed March 3, 2022.
                                3. O'Brien S. Biden renews call to let Medicare negotiate drug prices, an effort that has stalled in Congress. CNBC. https://www.cnbc.com/2022/03/02/biden-renews-call-to-let-medicare-negotiate-drug-prices.html. Published March 2, 2022. Accessed March 3, 2022.
                                4. Dunleavy K. A year later at the SOTU, Deja Vu all over again as Biden calls for lower drug prices, zeroing in on Insulin. Fierce Pharma. https://www.fiercepharma.com/pharma/year-later-sotu-deja-vu-all-over-again-biden-calls-lower-drug-prices-zeroing-insulin. Published March 2, 2022. Accessed March 3, 2022.
                                5. FDA Approves Pacritinib for Myelofibrosis and Thrombocytopenia https://www.pharmacytimes.com/view/fda-approves-pacritinib-for-myelofibrosis-and-thrombocytopenia. Published March 1, 2022. Accessed March 2, 2022.
                                6. FDA Permits Marketing of First Condom Specifically Indicated for Anal Intercourse. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-condom-specifically-indicated-anal-intercourse. Published February 23, 2022. Accessed February 24, 2022.
                                7. Schedule of dates. ASHP Match | Schedule. https://natmatch.com/ashprmp/schedule.html. Published January 6, 2022. Accessed March 3, 2022.
                                8. Summary Results of the Phase I Match for Positions Beginning in 2021. American Society of Health-System Pharmacists Resident Matching Program. https://natmatch.com/ashprmp/stats/2021applstats-ph1.pdf. Accessed March 3, 2022.
                                  9. 4 min
                                9. February 25, 2022

                                  This week on Pharm5:

                                  • Stem cell transplant led to HIV remission
                                  • Pyrukynd approved for PK-deficient hemolytic anemia
                                  • TicoVac recommended for tick-borne encephalitis
                                  • New PBM regulation passed in Michigan
                                  • FTC fails to pass PBM investigation proposal


                                    • Connect with us!

                                    • Listen to our podcast: Pharm5
                                    • Watch us on TikTok: @LizHearnPharmD
                                    • Follow us on Twitter: @LizHearnPharmD


                                      • References:

                                      1. HIV: Stem cell transplant may have cured woman. Medical News Today. https://www.medicalnewstoday.com/articles/stem-cell-treatment-may-have-cured-woman-of-hiv#Not-a-universal-cure. Accessed February 24, 2022.
                                      2. FDA approvals roundup: Pyrukynd and Solosec. Regulatory Affairs Professionals Society (RAPS). https://www.raps.org/news-and-articles/news-articles/2022/2/fda-approvals-roundup-pyrukynd-nalmefene-hcl-solos. Accessed February 24, 2022.
                                      3. Pyrukynd [package insert]. U.S. Food and Drug Administration Website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216196s000lbl.pdf. Revised February 2022.
                                      4. CDC Advisory Committee on Immunization Practices Votes to recommend ticovac™, Pfizer's tick-borne encephalitis (TBE) vaccine, for those at risk of virus exposure. Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/cdc-advisory-committee-immunization-practices-votes. Accessed February 24, 2022.
                                      5. Morgan LW, Knowles EP, 17 F. Michigan Pharmacy Benefit Manager (PBM) Bill Passes the Senate. Frier Levitt - Attorneys at Law. https://www.frierlevitt.com/articles/michigan-pharmacy-benefit-manager-pbm-bill-passes-the-senate/. Published February 17, 2022. Accessed February 24, 2022.
                                      6. Barrett J. PBM reform legislation progresses in Michigan. Drug Topics. https://www.drugtopics.com/view/pbm-reform-legislation-progresses-in-michigan. Published March 26, 2021. Accessed February 24, 2022.
                                      7. Pharmacypracticenews.com. https://www.pharmacypracticenews.com/Online-First/Article/02-22/FTC-Votes-Against-Investigating-PBMs-Effects-on-Specialty-Pharmacies/66213. Accessed February 24, 2022.
                                      8. Rowland D. Federal Trade Commission rejects Pharmacy Benefit Managers Probe pushed by Biden appointee. The Columbus Dispatch. https://www.dispatch.com/story/news/2022/02/17/prescription-drug-costs-ftc-declines-go-after-pbms-despite-pharmacists-testimony/6787109001/. Published February 18, 2022. Accessed February 24, 2022.
                                        9. 5 min
                                      9. February 18, 2022

                                        This week on Pharm5:

                                        • 2022 ASHP Match Rankings now open
                                        • Pfizer-BioNTech COVID-19 vaccine on hold for kids <5; bebtelovimab granted EAU
                                        • Eversense E3 implanted CGM with 180-day lifespan approved for adults with diabetes
                                        • NDA submitted for adagrasib therapy for KRAS G12C mutation non-small cell lung cancer
                                        • New York Times highlights current strain on U.S. community pharmacies


                                          • References:

                                          1. Schedule of dates. ASHP Match | Schedule. https://natmatch.com/ashprmp/schedule.html. Published January 6, 2022. Accessed February 17, 2022.
                                          2. Matching algorithm. ASHP Match | The Matching Algorithm. https://natmatch.com/ashprmp/algorithm.html. Published January 6, 2022. Accessed February 17, 2022.
                                          3. Hur K. Pfizer director dr. Scott Gottlieb: Shots for kids under 5 delayed due to low Covid cases in trial. CNBC. https://www.cnbc.com/2022/02/14/pfizer-director-dr-scott-gottlieb-shots-for-kids-under-5-delayed-due-to-low-covid-cases-in-trial.html. Published February 14, 2022. Accessed February 17, 2022.
                                          4. Coronavirus (COVID-19) update: FDA authorizes new monoclonal antibody for treatment of COVID-19 that retains activity against Omicron variant. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains. Accessed February 17, 2022.
                                          5. Garza M, Mahoney K. 180-day implantable CGM, Eversense E3, approved by the FDA. diaTribe. https://diatribe.org/180-day-implantable-cgm-eversense-e3-approved-fda. Published February 14, 2022. Accessed February 17, 2022.
                                          6. FDA accepts NDA for Adagrasib for non-small cell lung cancer. Pharmacy Times. https://www.pharmacytimes.com/view/fda-accepts-nda-for-adagrasib-for-non-small-cell-lung-cancer. Published February 16, 2022. Accessed February 17, 2022.
                                          7. Ngo M. Pharmacists Burned Out by Workload and Demands. The New York Times. February 14, 2022:1.


                                            8. Connect with us!

                                            • Listen to our podast: Pharm5
                                            • Watch us on TikTok: @LizHearnPharmD
                                            • Follow us on Twitter: @LizHearnPharmD
                                              • 4 min
                                            • February 11, 2022

                                              This week on Pharm5:

                                              • CVS and Walgreens lift limits on at-home COVID-19 tests
                                              • Enjaymo (sutimlimab) approved for use in adults with cold agglutinin disease
                                              • The FDA’s draft guidance for development of non-opioid analgesics is open for public comments until April 11th, 2022
                                              • SURPASS-5 shows promising results for A1c lowering and weight loss at 40-weeks with tirzepatide
                                              • Mark Cuban’s CostPlus Drug Company has launched with limited formulary


                                                • References:

                                                1. Oshin O. CVs, Walgreens remove limits on at-home covid-19 tests. TheHill. https://thehill.com/policy/healthcare/public-global-health/593033-cvs-walgreens-remove-limits-on-at-home-covid-19-tests. Published February 6, 2022. Accessed February 10, 2022.
                                                2. Enjaymo [package insert]. U.S. Food and Drug Administration Website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761164s000lbl.pdf?utm_medium=email&utm_source=govdelivery. Revised February 2022.
                                                3. Cold agglutinin disease. NORD (National Organization for Rare Disorders). https://rarediseases.org/rare-diseases/cold-agglutinin-disease/#:~:text=Cold%20agglutinin%20disease%20(CAD)%20is,subtype%20of%20autoimmune%20hemolytic%20anemia. Published November 17, 2020. Accessed February 10, 2022.
                                                4. Commissioner of the FDA takes steps aimed at fostering development of non-addictive alternatives to opioids for acute pain management. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-takes-steps-aimed-fostering-development-non-addictive-alternatives-opioids-acute-pain-management?utm_campaign=&utm_content=1644424858&utm_medium=FDA%2CU.S.%2BFood%2Band%2BDrug%2BAdministration&utm_source=facebook%2Clinkedin. Accessed February 10, 2022.
                                                5. Center for Drug Evaluation and Research. Development of non-opioid analgesics for acute pain; draft guidance fo. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-non-opioid-analgesics-acute-pain-draft-guidance-industry. Accessed February 10, 2022.
                                                6. Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes. JAMA. 2022;327(6):534. doi:10.1001/jama.2022.0078
                                                7. Costplusdrugs.com. https://costplusdrugs.com/. Accessed February 10, 2022.


                                                  8. Connect with us!

                                                  • Listen to our podcast: Pharm5
                                                  • Watch us on TikTok: @LizHearnPharmD
                                                  • Follow us on Twitter: @LizHearnPharmD
                                                    • 4 min
                                                  • Introducing: Pharm5
                                                    Coming February 2022 - Pharm5! The top five things happening in pharmacy this week in five minutes or less! Hosted by assistant professor of pharmacotherapy and board certified ambulatory care pharmacist, Dr. Elizabeth B. Hearn.
                                                    1 min

                                                  About Pharm5

                                                  From the publisher's feed

                                                  The top five things happening in pharmacy this week in five minutes or less! Hosted by assistant professor of pharmacotherapy and board certified ambulatory care pharmacist, Dr. Elizabeth B. Hearn.